Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term follow-up of vatelizumab in relapsing-remitting multiple sclerosis
2014-003265-19Phase 2Terminated
- Sponsor
- Sanofi
- Start
- Feb 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vatelizumab in relapsing-remitting multiple sclerosis (RRMS), sponsored by Sanofi. Primary endpoint: Number of treatment-emergent adverse events. Started Feb 2015; status: terminated.
02
Drugs
vatelizumab
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on 2014-003265-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003265-19.